Palatin Technologies, Inc. Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists Annual Meeting
September 27, 2021 at 07:30 am EDT
Palatin Technologies, Inc. announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models of retinopathy, at the 2021 Annual Meeting of the American Society of Retina Specialists (ASRS), being held virtually October 8-12, 2021. The presentation highlights the positive pre-clinical data in mouse models of retinopathy, and the possible utility of melanocortin receptor agonists in the treatment of diabetic retinopathy and choroidal neovascularization.